CA Patent

CA2866683A1 — High concentration alpha-glucosidase compositions for the treatment of pompe disease

Assigned to Amicus Therapeutics Inc · Expires 2013-09-12 · 13y expired

What this patent protects

The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid a-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of …

USPTO Abstract

The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid a-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid a-glucosidase enzyme formulation.

Drugs covered by this patent

Patent Metadata

Patent number
CA2866683A1
Jurisdiction
CA
Classification
—
Expires
2013-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Amicus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.